特应性皮炎外用治疗定量分析:润肤剂使用意外偏低,外用糖皮质激素与抑郁及并发哮喘强相关
该研究在约45万人口集水区对844例中重度特应性皮炎患者进行31年前瞻性双盲配药记录,量化外用糖皮质激素(TCS)和润肤剂使用。TCS使用与抗抑郁治疗强相关;结论认为润肤剂使用不足可能是AD严重度的 contributing factor,TCS使用未超过现行指南。
要点
- TCS用量与抗抑郁治疗及并发哮喘强相关
核心结论
- 润肤剂使用不足可能是特应性皮炎严重度的 contributing factor。
- 外用糖皮质激素的实际使用量未超过现行指南推荐。
- 外用糖皮质激素使用与抗抑郁治疗及并发哮喘强相关。
研究设计与样本
- 基于人群的前瞻性队列研究,在约45万人口集水区内于药品配发点进行双盲配药记录。
- 纳入844例在初级保健中疾病控制失败的中重度特应性皮炎患者,每例记录12个月配药数据。
- 另设独立验证队列重复验证结果。
主要发现
- TCS使用与抗抑郁治疗强相关。
关键数值与推荐
- 润肤剂实际用量约为现行指南推荐量的四分之一(原文:fourfold lower than the amount recommended)。
临床怎么用
- 临床应重视评估并纠正润肤剂使用不足,其可能与疾病严重度相关。
- TCS实际用量未超过指南,提示无需过度担忧TCS过度使用。
- 对合并哮喘或接受抗抑郁治疗的患者,应关注其TCS使用情况及疾病管理。
- 精确量化外用治疗用量可作为评估真实世界影响的可及策略。
局限性
- 研究基于初级保健中疾病控制失败的人群,结果外推需谨慎。
- 配药记录反映处方配发量,未必完全等同于患者实际使用量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite decades of use, the actual amounts of topical corticosteroids (TCS) and emollients used in moderate-to-severe atopic dermatitis (AD) under real-world conditions are unknown. Thus, it remains unclear whether inadequate use is widespread. OBJECTIVES: To quantify the use of TCS and emollients in moderate-to-severe AD. METHODS: Double-blinded drug prescribing was recorded prospectively at the point of drug dispensing within a catchment area of approximately 450 000 people over a 31-year period in a population-based cohort marked by failure of disease control in primary care (n = 844). For each patient, prescribing was recorded over a 12-month period in order to minimize fluctuations. RESULTS: This approach resulted in a near-complete dataset, which was essentially free of reporting bias and recording bias. Atopic comorbidities matched expected frequencies. Median use of TCS was statistically significantly higher in juvenile patients (age < 16 years) compared with adult patients (49·2 vs. 38·1 g per month), in male vs. female patients (46·8 vs. 29·7 g per month) and in patients receiving concurrent asthma treatment (40·4 vs. 26·7 g per month). TCS use was strongly associated with antidepressant treatment. Emollient use was unexpectedly low with a median of 9·6 g per day (range 1·4-30·1). Results were replicated in an independent validation cohort. CONCLUSIONS: Deficient use of emollients may be a factor contributing to AD severity. Our analysis showed that the use of TCS does not exceed current guidelines. Accurate quantification of topical treatments provides a widely accessible strategy to measure the real-world impact of novel AD treatments. What's already known about this topic? Both emollient and topical corticosteroid (TCS) use have been a mainstay of atopic dermatitis (AD) treatment for over 60 years. The actual quantities used by patients under real-world conditions are unknown. What does this study add? The real-world use of emollients is fourfold lower than the amount recommended in current guidelines. Underuse of emollients may be a significant factor in disease exacerbation. The use of TCS is significantly higher in male patients and is higher in patients with AD who also have asthma. The use of TCS is strongly associated with concurrent antidepressant treatment.
引用
- Choi JY, Dawe R, Ibbotson S, et al. Quantitative analysis of topical treatments in atopic dermatitis: unexpectedly low use of emollients and strong correlation of topical corticosteroid use both with depression and concurrent asthma. Br J Dermatol. 2019. PMID: 31257575. doi:10.1111/bjd.18265
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。